GlassScriptPhysician profile
Kyle Guterba
NPI 1093239717
$70,433.96
in general payments reported to CMS, 2019-2025
28 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,434 · 2022: $2,611 · 2023: $29K · 2024: $17K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $17K · Honoraria: $12K · Food and Beverage: $9,048 · Travel and Lodging: $5,766 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,175.00 |
| Consulting Fee | $17,388.00 |
| Honoraria | $11,863.00 |
| Food and Beverage | $9,048.08 |
| Travel and Lodging | $5,765.50 |
| Education | $148.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $34,636.59 | 2023-2025 | Auvelity |
| Abbvie INC. | $27,007.69 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,364.72 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,205.80 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $1,056.81 | 2021-2025 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $910.38 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $839.71 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $557.23 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $504.03 | 2021-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $375.98 | 2021-2025 | Invega Sustenna, Invega, Spravato |
| E.R. Squibb & Sons, L.L.C. | $333.58 | 2024-2025 | Cobenfy |
| Corium, LLC | $309.94 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $235.52 | 2021-2023 | Trintellix |
| Eisai INC. | $198.82 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $188.98 | 2021-2023 | Qelbree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $157.37 | 2021-2025 | Loreev Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $112.96 | 2024 | Abilify Asimtufii, Rexulti |
| Genzyme Corporation | $107.20 | 2025 | |
| Neos Therapeutics, LP | $58.48 | 2023 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $55.06 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $43.61 | 2022 | |
| Noven Therapeutics, LLC | $41.96 | 2021-2023 | Secuado |
| Validus Pharmaceuticals LLC | $38.29 | 2022-2023 | Equetro |
| Adlon Therapeutics L.P. | $21.00 | 2021 | |
| Allergan, INC. | $20.77 | 2021 | |
| Noven Pharmaceuticals, INC. | $20.29 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.18 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Guterba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.